Publication of year-end report 2025/2026
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - June 2026. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. “The 2025/2026 financial year marked a significant step forward for ODI Pharma, with substantially higher sales, improved profitability and a strengthened position in our core market. We completed the year with
vor 12 Stunden2 Min. Lesezeit
ODI Pharma completes final loan repayment and becomes debt-free
ODI Pharma AB (“ODI” or the “Company”) announces that it has completed the final repayment of its outstanding working capital loan and is now debt-free. Volker Wiederrich, Chairman of the Board, ODI Pharma, comments: "The full repayment of the loan marks the completion of a financing arrangement that supported the Company's commercial expansion. With no remaining interest-bearing liabilities, ODI Pharma enters its next phase with a strengthened balance sheet and increased fin
2. Juni2 Min. Lesezeit
Publication of interim report Q3 2025/2026
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - March 2026. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. “ODI Pharma continues to deliver significant and consistent commercial growth, supported by a more stable market environment and improved operating conditions. Over the past three quarters, the Company has achi
28. Mai2 Min. Lesezeit




